Objective: To study the effects of Weipixiao(胃痞消, WPX) on Wnt pathway-associated proteins in gastric mucosal epithelial cells from rats with gastric precancerous lesions(GPL). Methods: Sprague Dawley rats were randomly divided into control, model, vitacoenzyme(0.2 g·kg~(-1)·day~(-1)), WPX high-dose(H-WPX, 15 g·kg~(-1)·day~(-1)), WPX medium-dose(M-WPX, 7.5 g·kg~(-1)·day~(-1)) and WPX low-dose(L-WPX, 3.75 g·kg~(-1)·day~(-1)) groups. After successfully establishing the GPL model, the rats were consecutively administered WPX or vitacoenzyme by gastrogavage for 10 weeks. Differential expression of Leucine-rich repeat-containing G-proteincoupled receptor 5(Lgr5), matrix metalloproteinase-7(MMP-7), Wnt1, Wnt3 a, and β-catenin in gastric mucosal epithelial cells in all groups were immunohistochemically detected, and the images were taken and analyzed semiquantitatively by image pro plus 6.0 software. Results: Gastric epithelium in the model group showed significantly higher expression levels of Lgr5, MMP-7, Wnt1, Wnt3 a and β-catenin than those of the control group(P<0.01). Interestingly, we also observed Lgr5+ cells, which generally located at the base of the gastric glandular unit, migrated to the luminal side of gastric epithelium with GPL. The expression levels of Lgr5, MMP-7, Wnt1, and β-catenin were all down-regulated in the L-WPX group as compared with those of both model and vitacoenzyme groups(P<0.05). A similar, but nonsignificant down-regulation in expression level of Wnt3 a was noted in all WPX groups(P>0.05). Conclusion: Our findings suggested that the therapeutic mechanisms of WPX in treating GPL might be related with its inhibitory effects on the expressions of Lgr5, MMP-7, Wnt1, β-catenin and the aberrant activation of Wnt/β-catenin pathway. Objective: To study the effects of Weipixiao on Wnt pathway-associated proteins in gastric mucosal epithelial cells from rats with gastric precancerous lesions (GPL). Methods: Sprague Dawley rats were randomly divided into control, model, vitacoenzyme (0.2 g · kg -1 day -1), WPX high-dose (15 g · kg -1 day -1), WPX medium-dose (M-WPX, 7.5 g · kg -1 day -1) and WPX low-dose (L-WPX, 3.75 g · kg -1 day -1) groups . After successfully establishing the GPL model, the mice were either sequentially ligated with WPX or vitacoenzyme by gastrogavage for 10 weeks. Differential expression of Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5), matrix metalloproteinase-7 Wnt1, Wnt3 a, and β-catenin in gastric mucosal epithelial cells in all groups were immunohistochemically detected, and the images were taken and analyzed semiquantitatively by image pro plus 6.0 software. Results: Gastric epithelium in the model group showed significantly higher expr eingly levels of Lgr5, MMP-7, Wnt1, Wnt3 a and β-catenin than those of the control group (P <0.01). Interestingly, we also observed Lgr5 + cells, which generally located at the base of the gastric glandular unit, migrated to the luminal side of gastric epithelium with GPL. The expression levels of Lgr5, MMP-7, Wnt1, and β-catenin were all down-regulated in the L-WPX group as compared with those of both model and vitacoenzyme groups (P < 0.05). A similar, but nonsignificant down-regulation in expression level of Wnt3 a was noted in all WPX groups (P> 0.05). Conclusion: Our findings suggested that the therapeutic mechanisms of WPX in treating GPL might be related with its inhibitory effects on the expressions of Lgr5, MMP-7, Wnt1, β-catenin and the aberrant activation of Wnt / β-catenin pathway.